Current Problems in Cancer
Volume 34, Issue 3 , Pages 211-227 , May 2010

ACR Appropriateness Criteria®: Follow-Up of Hodgkin's Lymphoma

References 

  1. Jerusalem G, Beguin Y, Fassotte MF, Belhocine T, Hustinx R, Rigo P, et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin disease. Ann Oncol. 2003;14:123–130
  2. Radford JA, Eardley A, Woodman C, Crowther D. Follow up policy after treatment for Hodgkin disease: too many clinic visits and routine tests? (A review of hospital records). BMJ. 1997;314:343–346
  3. Torrey MJ, Poen JC, Hoppe RT. Detection of relapse in early-stage Hodgkin disease: role of routine follow-up studies. J Clin Oncol. 1997;15:1123–1130
  4. Dryver ET, Jernstrom H, Tompkins K, Buckstein R, Imrie KR. Follow-up of patients with Hodgkin disease following curative treatment: the routine CT scan is of little value. Br J Cancer. 2003;89:482–486
  5. Zinzani PL, Stefoni V, Tani M, Fanti S, Musuraca G, Castellucci P, et al. Role of [18F] fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol. 2009;27:1781–1787
  6. Xavier MF, Schuster SJ, Andreadis C, et al. Detection of relapse in diffuse large B-cell lymphoma (DLBCL) and Hodgkin's lymphoma (HL): observations and implications for post-remission radiologic surveillance. ASH Annual Meeting Abstracts. 2006;108:2428
  7. Basciano BA, Moskowitz C, Zelenetz AD. Impact of routine surveillance imaging on the outcome of patients with relapsed Hodgkin lymphoma. ASH Annual Meeting Abstracts. 2009;114:1558
  8. Guadagnolo BA, Punglia RS, Kuntz KM, Mauch PM, Ng AK. Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin disease. J Clin Oncol. 2006;24:4116–4122
  9. Hueltenschmidt B, Sautter-Bihl ML, Lang O, Maul FD, Fischer J, Mergenthaler HG, et al. Whole body positron emission tomography in the treatment of Hodgkin disease. Cancer. 2001;91:302–310
  10. Mikosch P, Gallowitsch HJ, Zinke-Cerwenka W, Heinisch M, Pipam W, Eibl M, et al. Accuracy of whole-body 18F–FDP-PET for restaging malignant lymphoma. Acta Med Austriaca. 2003;30:41–47
  11. Cerci JJ, Trindade E, Pracchia LF, Pitella FA, Linardi CC, Soares J, et al. Cost effectiveness of positron emission tomography in patients with Hodgkin's lymphoma in unconfirmed complete remission or partial remission after first-line therapy. J Clin Oncol. 2010;28:1415–1421
  12. Cheson BD. The International Harmonization Project for response criteria in lymphoma clinical trials. Hematol Oncol Clin North Am. 2007;21:841–854
  13. Mocikova H, Obrtlikova P, Vackova B, Trneny M. Positron emission tomography at the end of first-line therapy and during follow-up in patients with Hodgkin lymphoma: a retrospective study. Ann Oncol. 2009;Epub ahead of print
  14. Zuckerman D, Lacasce A, Jacobsen E, et al. High false positive rate with the use of CT and FDG-PET in post-remission surveillance for Hodgkin lymphoma. ASH Annual Meeting Abstracts. 2007;110:2327
  15. Maeda LS, Horning SJ, Iagaru AH, et al. Role of FDG-PET/CT surveillance for patients with classical Hodgkin's disease in first complete response: The Stanford University Experience. ASH Annual Meeting Abstracts. 2009;114:1563
  16. Hodgson DC, Gilbert ES, Dores GM, Schonfeld SJ, Lynch CF, Storm H, et al. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol. 2007;25:1489–1497
  17. Inskip PD, Robison LL, Stovall M, Smith SA, Hammond S, Mertens AC, et al. Radiation dose and breast cancer risk in the childhood cancer survivor study. J Clin Oncol. 2009;27:3901–3907
  18. Travis LB, Hill DA, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. J Am Med Assoc. 2003;290:465–475
  19. van Leeuwen FE, Klokman WJ, Stovall M, Dahler EC, van't Veer MB, Noordijk EM, et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst. 2003;95:971–980
  20. De Bruin ML, Sparidans J, Van'T Veer MB, Noordijk EM, Louwman MW, Zijlstra JM, et al. Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes. J Clin Oncol. 2009;27:4239–4246
  21. Franklin J, Pluetschow A, Paus M, Specht L, Anselmo AP, Aviles A, et al. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. Ann Oncol. 2006;17:1749–1760
  22. Yahalom J, Petrek JA, Biddinger PW, Kessler S, Dershaw DD, McCormick B, et al. Breast cancer in patients irradiated for Hodgkin's disease: a clinical and pathologic analysis of 45 events in 37 patients. J Clin Oncol. 1992;10:1674–1681
  23. Diller L, Medeiros Nancarrow C, Shaffer K, Matulonis U, Mauch P, Neuberg D, et al. Breast cancer screening in women previously treated for Hodgkin's disease: a prospective cohort study. J Clin Oncol. 2002;20:2085–2091
  24. Wolden SL, Hancock SL, Carlson RW, Goffinet DR, Jeffrey SS, Hoppe RT. Management of breast cancer after Hodgkin's disease. J Clin Oncol. 2000;18:765–772
  25. Lee L, Pintilie M, Hodgson DC, Goss PE, Crump M. Screening mammography for young women treated with supradiaphragmatic radiation for Hodgkin's lymphoma. Ann Oncol. 2008;19:62–67
  26. Kwong A, Hancock SL, Bloom JR, Pal S, Birdwell RL, Mariscal C, et al. Mammographic screening in women at increased risk of breast cancer after treatment of Hodgkin's disease. Breast J. 2008;14:39–48
  27. Warner E, Messersmith H, Causer P, Eisen A, Shumak R, Plewes D. Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med. 2008;148:671–679
  28. American College of Radiology. ACR Practice Guideline for the performance of contrast-enhanced magnetic resonance imaging (MRI) of the breast. http://www.acr.org/SecondaryMainMenuCategories/quality_safety/guidelines/breast/mri_breast.aspxAccessed January 7, 2010
  29. Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57:75–89
  30. Swerdlow AJ, Barber JA, Hudson GV, Cunningham D, Gupta RK, Hancock BW, et al. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol. 2000;18:498–509
  31. Swerdlow AJ, Schoemaker MJ, Allerton R, Horwich A, Barber JA, Cunningham D, et al. Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment. J Clin Oncol. 2001;19:1610–1618
  32. Travis LB, Gospodarowicz M, Curtis RE, Clarke EA, Andersson M, Glimelius B, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst. 2002;94:182–192
  33. van Leeuwen FE, Klokman WJ, Stovall M, Hagenbeek A, van den Belt-Dusebout AW, Noyon R, et al. Roles of radiotherapy and smoking in lung cancer following Hodgkin disease. J Natl Cancer Inst. 1995;87:1530–1537
  34. Ng AK, Bernardo MV, Weller E, Backstrand K, Silver B, Marcus KC, et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood. 2002;100:1989–1996
  35. Das P, Ng AK, Earle CC, Mauch PM, Kuntz KM. Computed tomography screening for lung cancer in Hodgkin's lymphoma survivors: decision analysis and cost-effectiveness analysis. Ann Oncol. 2006;17:785–793
  36. Eriksson F, Gagliardi G, Liedberg A, Lax I, Lee C, Levitt S, et al. Long-term cardiac mortality following radiation therapy for Hodgkin's disease: analysis with the relative seriality model. Radiother Oncol. 2000;55:153–162
  37. Hoppe RT. Hodgkin's disease: complications of therapy and excess mortality. Ann Oncol. 1997;8(suppl 1):115–118
  38. Carver JR, Shapiro CL, Ng A, Jacobs L, Schwartz C, Virgo KS, et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol. 2007;25:3991–4008
  39. Glanzmann C, Huguenin P, Lutolf UM, Maire R, Jenni R, Gumppenberg V. Cardiac lesions after mediastinal irradiation for Hodgkin's disease. Radiother Oncol. 1994;30:43–54
  40. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. J Am Med Assoc. 1993;270:1949–1955
  41. Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. J Am Med Assoc. 2003;290:2831–2837
  42. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, van't Veer MB, Baaijens MH, de Boer JP, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007;109:1878–1886
  43. Chen AB, Punglia RS, Kuntz KM, Mauch PM, Ng AK. Cost effectiveness and screening interval of lipid screening in Hodgkin's lymphoma survivors. J Clin Oncol. 2009;27:5383–5389
  44. Heidenreich PA, Hancock SL, Lee BK, Mariscal CS, Schnittger I. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol. 2003;42:743–749
  45. Heidenreich PA, Hancock SL, Vagelos RH, Lee BK, Schnittger I. Diastolic dysfunction after mediastinal irradiation. Am Heart J. 2005;150:977–982
  46. Heidenreich PA, Schnittger I, Strauss HW, Vagelos RH, Lee BK, Mariscal CS, et al. Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease. J Clin Oncol. 2007;25:43–49
  47. Adams MJ, Lipsitz SR, Colan SD, Tarbell ST, Diller L, Greenbaum N, et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol. 2004;22:3139–3148
  48. Bowers DC, McNeil DE, Liu Y, Yasui Y, Stovall M, Gurney JG, et al. Stroke as a late treatment effect of Hodgkin's disease: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2005;23:6508–6515
  49. De Bruin ML, Dorresteijn LD, Van'T Veer MB, Krol AD, van der Pal HJ, Kappelle AC, et al. Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. J Natl Cancer Inst. 2009;101:928–937
  50. Hancock SL, Cox RS, McDougall IR. Thyroid diseases after treatment of Hodgkin's disease. N Engl J Med. 1991;325:599–605
  51. Sklar C, Whitton J, Mertens A, Stovall M, Green D, Marina N, et al. Abnormalities of the thyroid in survivors of Hodgkin's disease: data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2000;85:3227–3232
  52. Koh ES, Sun A, Tran TH, Tsang R, Pintilie M, Hodgson DC, et al. Clinical dose-volume histogram analysis in predicting radiation pneumonitis in Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys. 2006;66:223–228
  53. Ng AK, Li S, Neuberg D, Chi R, Fisher DC, Silver B, et al. A prospective study of pulmonary function in Hodgkin's lymphoma patients. Ann Oncol. 2008;19:1754–1758
  54. Tarbell NJ, Thompson L, Mauch P. Thoracic irradiation in Hodgkin's disease: disease control and long-term complications. Int J Radiat Oncol Biol Phys. 1990;18:275–281
  55. Knobel H, Havard Loge J, Brit Lund M, Forfang K, Nome O, Kaasa S. Late medical complications and fatigue in Hodgkin's disease survivors. J Clin Oncol. 2001;19:3226–3233
  56. Hirsch A, Vander Els N, Straus DJ, Gomez EG, Leung D, Portlock CS, et al. Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease. J Clin Oncol. 1996;14:1297–1305
  57. Horning SJ, Adhikari A, Rizk N, Hoppe RT, Olshen RA. Effect of treatment for Hodgkin's disease on pulmonary function: results of a prospective study. J Clin Oncol. 1994;12:297–305
  58. Hodgson DC, Pintilie M, Gitterman L, Dewitt B, Buckley CA, Ahmed S, et al. Fertility among female Hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy. Hematol Oncol. 2007;25:11–15
  59. Kulkarni SS, Sastry PS, Saikia TK, Parikh PM, Gopal R, Advani SH. Gonadal function following ABVD therapy for Hodgkin's disease. Am J Clin Oncol. 1997;20:354–357
  60. Behringer K, Breuer K, Reineke T, May M, Nogova L, Klimm B, et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2005;23:7555–7564
  61. Sieniawski M, Reineke T, Nogova L, Josting A, Pfistner B, Diehl V, et al. Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). Blood. 2008;111:71–76
  62. Mauch P, Ng A, Aleman B, Carde P, Constine L, Diehl V, et al. Report from the Rockefellar Foundation Sponsored International workshop on reducing mortality and improving quality of life in long-term survivors of Hodgkin's disease: July 9-16, 2003, Bellagio, Italy. Eur J Haematol Suppl. 2005;68–76
  63. Ng AK, Mauch PM. Late effects of Hodgkin's disease and its treatment. Cancer J. 2009;15:164–168

 The American College of Radiology seeks and encourages collaboration with other organizations on the development of the ACR Appropriateness Criteria through society representation on expert panels. Participation by representatives from collaborating societies on the expert panel does not necessarily imply society endorsement of the final document.

 Copyright © 2010 American College of Radiology. Reprinted with permission of the American College of Radiology.

PII: S0147-0272(10)00048-6

doi: 10.1016/j.currproblcancer.2010.04.007

Current Problems in Cancer
Volume 34, Issue 3 , Pages 211-227 , May 2010

Article Tools